Pharmacyte Biotech Inc (OTCMKTS:PMCB) was a notable decliner during Monday’s trading session. The stock collapsed by close to 2 percent on relatively high volumes, which were 2 times the daily average. The stock has been showing weakness ever since the stock was unable to move above the resistance zone of $0.1246. The stock currently trades below all daily moving averages. The indicator for relative strength continues to trend lower and has given a sell signal. The MACD oscillator has given a sell signal, which is considered to be bearish. Traders see the stock could head to levels of $0.080 in the near term

Pharmacyte Biotech Inc (OTCMKTS:PMCB) has decided to make some changes in the advisory board by appointing new international diabetes expert. As per the reports, Prof. Hans-Peter Hammes, M.D has been named as one of the scientific advisory board members at Pharmacyte Biotech.

Insights On The Matter

Prof. Hammes is one of the most sought after and globally recognized figures in the medical science field. His expertise and knowledge in the treatments of diabetes and its complications can be valuable for any organization and help it serve customers in an effective manner. Along with appointment as a board member, Prof. Hammes will also be a member of International Diabetes Consortium of the company. He will provide his insightful advice to Pharmacyte as and when needed.

The senior management team of the company is delighted to have him onboard and hopes that he will assist Pharmacyte to the best of his knowledge. According to Kenneth L. Waggoner, Chief Executive Officer, Pharmacyte, it’s an honor for the company to have a global figure like Prof. Hammes on its advisory panel. All the experts at Pharmacyte will try to make the best use of this opportunity and enhance their knowledge level.

He is Europe’s one of the very few experts who knows more than anyone else about Diabetes. Pharmacyte looks forward to using his knowledge to develop many advanced diabetes treatments in the coming months. During the recently held annual meeting of the Consortium in Austria, he participated with sheer enthusiasm that left all the participants speechless. This shows his wealth of knowledge and how useful can it be for the human race.

He previously helped Pharmacyte in the development of insulin-dependent diabetes. The end results lived up to everyone’s expectations, which is why the management had decided right then to request him to join the scientific advisory board of Pharmacyte. Further updates about his contribution will be shared from time to time.